Статья
ПАТОГЕНЕТИЧЕСКИЕ ФАКТОРЫ ИБС И ИНФЕКЦИЯ HELICOBACTER PYLORI
В обзоре научных публикаций рассмотрены патогенетические этапы хронического воспалительного процесса, являющегося фактором развития осложнений атеросклероза и прогрессирования ИБС. Приведены выявленные факторы атерогенного влияния инфекции Helicobacter pylori на течение ИБС.
1. Goldberg R.J., Glatfelter К., Burbank-Schmidt Е. et al. Trends in community mortality due to coronary heart disease. Am. Heart J. 2006; (151) 2: 501–07.
2. Oschepkova E.V. Death rate of the population from cardiovascular disease in the Russian Federation in 2001–2006 and ways on its decrease. Cardiology 2009; 2: 67–72. Russian (Ощепкова Е.В. Смертность населения от сердечно-сосудистых заболеваний в Российской Федерации в 2001–2006 гг. и пути по её снижению. Кардиология 2009; 2: 67–72.)
3. Public health services in Russia. 2011 Stat. collection Rosstat. М, 2011; 326. Russian (Здравоохранение в России. 2011 Стат. сб. Росстат.М., 2011; 326.)
4. Graziansky N.A. Non-stable stenocardia – a sharp coronary syndrome without liftings of segment ST. Antithrombotic treatment. Cardiology 2000; 12: 12–25. Russian (Грацианский Н.А. Нестабильная стенокардия – острый коронарный синдром без подъёмов сегмента ST. Антитромботическое лечение. Кардиология 2000; 12: 12–25.)
5. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (First of two parts). N. Engl.J. Med. 1992; 326: 242–50.
6. Deanfield J.Е., Halcox J.P., Rabelink Т.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285–95.
7. Libby Р., Ridker Р.М., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43.
8. Sumarokov A.B., Naumov V. G, Masenko V.P. С-reactivity protein and cardiovascular pathology. М: Triada 2006; 178. Russian (Сумароков А.Б., Наумов В.Г., Масенко В.П. С-реактивный белок и сердечно-сосудистая патология.М.: Изд-во “Триада” 2006; 178.)
9. Amar J., Fauvel J., Drouet L. et al. Interleukin 6 is associated with subclinical atherosclerosis: а link with soluble intercellular adhesion molecular I.J. Hypertens. 2006; (24) 6: 1083–88.
10. Dinarello С.А. Interleukin 1 beta and interleukin 18 as mediators of inflammation and the aging process. Am.J. Clin. Nutr. 2006; (83) 2: 447S-55S.
11. Schomig К., Buch G., Stehhich В. et al. Interleukin-8 is associated with circulating CD133+ progenitor cells in acute myocardial infarction. Eur. Heart J. 2006; 27: 1032–37.
12. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 2006; 86: 515–81.
13. Rebrov A.P., Voskoboj I.V. A role of inflammatory and infectious factors in atherosclerosis development. Therapeutic archive 2004; 1: 78–82. Russian (Ребров А. П., Воскобой И.В. Роль воспалительных и инфекционных факторов в развитии атеросклероза. Терапевтический архив 2004; 1: 78–82).
14. Truhina N.A., Atamanova T.JU. Effect of dislipoproteinemia on a condition of immune system and a hemostasis at IHD patients. Medical immunology 2004; (6) 3–5: 320. Russian (Трухина Н.А., Атаманова Т.Ю. Влияние дислипопротеинемии на состояние иммунной системы и гемостаз у больных ИБС. Медицинская иммунология 2004; (6) 3–5: 320.)
15. Lutaj M. I, Gavrilenko T.I., Kornilina E.M., et al. Cytokine-producing activity of mononuclear of peripheral blood at patients with a stable and unstable stenocardia. The congress of cardiologists of the CIS countries. Materials; St.-Petersburg, 2003: 174. Russian (Лутай М.И, Гавриленко Т.И., Корнилина Е.М. и др. Цитокинпродуцирующая активность мононуклеаров периферической крови у больных со стабильной и нестабильной стенокардией. Конгресс кардиологов стран СНГ. Материалы; Санкт-Петербург, 2003: 174.)
16. Park MJ., Choi S.H., Kim D. et al. Association between Helicobacter pylori Seropositivity and the Coronary Artery Calcium Score in a Screening Population. Gut Liver 2011; 5 (3): 321–27.
17. Jafarzadeh A., Esmaeeli-Nadimi A., Nemati M. et al. Serum concentrations of Helicobacter pylori IgG and the virulence factor CagA in patients with ischemic heart disease. East Mediterr Health J. 2010; 16: 1039–44.
18. Niccoli G., Franceschi F., Cosentino N. et al. Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron. Artery Dis. 2010; 21: 217–21.
19. Lazebnik L.B., Tsaregorodtseva T. M., Parfyonov A.I. Immune system and illnesses of digestive organs. Therapeutic archive 2004; 12: 5–8. Russian (Лазебник Л.Б., Царегородцева Т.М., Парфенов А.И. Иммунная система и болезни органов пищеварения. Терапевтический архив 2004; 12: 5–8.)
20. Pavlov O.N. Helicodacteriosis and coronary heart disease: sinthropic pathogenesis. Cardiovascular therapy and prevention 2009; 3: 54–61. Russian (Павлов О.Н. Патогенез синтропии хеликобактериоза и ишемической болезни сердца. Кардиоваскулярная терапия и профилактика 2009; 3: 54–61.)
21. Lazebnik L.B., Tsaregorodtseva T.M., Serova T.I. et al. Antibody to Helicobacter pylori at illnesses of a stomach. Therapeutic archive 2006; 2: 15–19. Russian (Лазебник Л.Б., Царегородцева Т.М., Серова Т.И. и др. Антитела к Helicobacter pylori при болезнях желудка. Терапевтический архив 2006; 2: 15–19.)
22. Neljubin V.N., Mudrov V.P. Immunopatological aspects of chronic inflammatory diseases of GIP. Medical immunology 2004; (6) 3–5: 320. Russian (Нелюбин В.Н., Мудров В.П. Иммунопатологические аспекты хронических воспалительных заболеваний ЖКТ. Медицинская иммунология 2004; (6) 3–5: 320.)
23. Chmiela М., Wisniewska М., Miszczak А. et al. Enhanced humoral response to Н.pylori or/ and Chlamydia spp. as а distinctive trait of patients with coronary heart disease (CHD). Gut 2002; 51 (Supp1.2): А77.
24. Strandberg T.E., Tilvis R.S., Vuoristo M. et al. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population. Br. Med.J. 1997; 314: 1317–18.
25. Patel P., Menall M.A. et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br. Med.J. 1995; 311: 711–14.
26. Pasceri V., Cammarota G., Patti G. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; (97) 17: 1675–79.
27. Laurila A., Bloigu A., Nayha S. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999; (142) 1: 207–10.
28. Kinjo K., Sato H., Shiotani I., Kurotobi T. et al. Osaka Acute Coronary Insufficiency Study (OACIS) Group. Prevalence of Helicobacter pylori infection and its link to coronary risk factors in Japanese patients with acute myocardial infarction. Circ.J. 2002; (66) 9: 805–10.
29. Martines Torres A., Martines Gaensly M. Helicobacter pylori: a new cardiovascular risk factor? Rev. Esp. Cardiol. 2002; (55) 6: 652–56.
30. Fraser A. G., Scragg R.K., Cox B., Jackson R. T. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern. Med.J. 2003; (33) 7: 267–72.
31. Oshima T., Ozono R., Yano Y., Teragawa H. et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects.J. Am. Coll. Cardiol. 2005; (45) 8: 1219–22.
32. Cai X.J., Cai H.B., Lu D. Study on the correlation of between infection, inflammation and coronary artery disease. Zhonghua Liu Xing Bing Xue Za Zhi 2003; (24) 6: 503–507.
33. Zhu J., Quyyumi A.A., Muhlestein J.B., Nieto F.J. et al. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. Am.J. Cardiol. 2002; (89) 2: 155–58.
34. Mayr M., Kiechl S., Mendall M.A., Willeit J. et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003; (34) 3: 610–15.
35. Jafarzadeh A., Esmaeeli-Nadimi A., Nemati M. et al. Serum concentrations of Helicobacter pylori IgG and the virulence factor CagA in patients with ischemic heart disease. East Mediterr Health J. 2010; (16) 10:1039–44.
36. Pellicano R., Parravicini P.P., Bigi R., Gandolfo N. et al. Infection by Helicobacter pylori and acute myocardial infarction. Do cytotoxic strains make a difference? New Microbiol. 2002; (25) 3: 315–21.
37. Yusuf S.W., Mishra R.M. Effect of Helicobacter pylori infection on fibrinogen level in elderly patients with ischemic heart disease. Acta Cardiol. 2002; (57) 5: 317–22.
38. Pellicano R., Oliaro E., Fagoonee S. et al. Clinical and biochemical parameters related to cardiovascular disease after Helicobacter pylori eradication. Int. Angiol. 2009; (28) 6: 469–73.
39. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.J. Physiol. Pharmacol. 2001; 52 (1 Suppl. 1): 3–31.
40. Migneco А., Ojetti V., Specchia L., et al. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter 2003; 8: 585–89.
41. Pellicano R., Peyre S., Astegiano M., Oliaro E. et al. Updated review (2006) on Helicobacter pylori as a potential target for the therapy of ischemic heart disease. Panminerva Med. 2006; 48 (4): 241–46.